MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology -- In-ear Infrasonic Hemodynography - to Achieve Cardiac Arrhythmia Assessment beyond that of ECG
CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ - MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology -- in-ear infrasonic hemodynography (IH) - for the monitoring of cardiac arrhythmias, resulting in insights beyond those that have been possible with state-of-the-art ECG monitoring. These results were presented at the Heart Rhythm Society meeting in Boston, July 30, 2021.
- The clinical trial for recruiting atrial fibrillation (AF) patients was approved by the institutional review board of The University of South Carolina School of Medicine.
- Synchronized MindMics In-ear Infrasonic Hemodynography (IH) data and ECG were simultaneously recorded from 15 patients in AF and 15 in SR for 20 minutes.
- Recruited AF patients were between the ages of 45 years and 90 years and showed a variety of arrhythmias.
- An oral presentation titled "MindMics: In-ear Infrasonic Hemodynography For Cardiac Arrhythmia Assessment Beyond ECG"was given at the Heart Rhythm Society 2021 Annual Meeting: Bringing the World of EP (Electrophysiology) Together on July 28-31.